Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NTRK Gene Fusion”

39 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 39 results

Not applicableNo Longer AvailableNCT03066661
What this trial is testing

Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

Who this might be right for
Cancers With NTRK, ROS1, or ALK Gene Fusions
Hoffmann-La Roche
Testing effectiveness (Phase 2)Ended earlyNCT04617054
What this trial is testing

Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion

Who this might be right for
Solid Tumor
Nuvation Bio Inc. 14
Early research (Phase 1)Study completedNCT03215511
What this trial is testing

Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

Who this might be right for
Solid Tumors Harboring NTRK Fusion
Bayer 81
Not applicableNo Longer AvailableNCT03206931
What this trial is testing

Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Who this might be right for
Solid Tumors Harboring NTRK Fusion
Bayer
Testing effectiveness (Phase 2)Active Not RecruitingNCT02637687
What this trial is testing

Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

Who this might be right for
Solid Tumors Harboring NTRK Fusion
Bayer 154
Early research (Phase 1)Ended earlyNCT03182257
What this trial is testing

Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors

Who this might be right for
Solid Tumor
Ono Pharmaceutical Co. Ltd 1
Early research (Phase 1)Study completedNCT06529445
What this trial is testing

Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects

Who this might be right for
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Jiangsu vcare pharmaceutical technology co., LTD 84
Testing effectiveness (Phase 2)Looking for participantsNCT07394374
What this trial is testing

CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities

Who this might be right for
Solid Tumors Harboring NTRK FusionNTRKNTRK Gene Fusion+1 more
Cullgen (Shanghai),Inc 42
Not applicableActive Not RecruitingNCT06780384
What this trial is testing

NTRK 1,2,3 Rearrangements in Patients With Solid Tumors

Who this might be right for
NTRK1/2/3 Fusion Gene Detection
Federico Cappuzzo 5,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT03834961
What this trial is testing

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

Who this might be right for
Central Nervous System NeoplasmInfantile FibrosarcomaRecurrent Acute Leukemia+2 more
Children's Oncology Group 33
Early research (Phase 1)Study completedNCT02122913
What this trial is testing

Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

Who this might be right for
Solid Tumors Harboring NTRK Fusion
Bayer 75
Not applicableUnknownNCT04921553
What this trial is testing

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

Who this might be right for
CancerCancer MetastaticNTRK Gene Fusion Overexpression+13 more
Centre Leon Berard 500
Testing effectiveness (Phase 2)Active Not RecruitingNCT02568267
What this trial is testing

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Who this might be right for
Breast CancerCholangiocarcinomaColorectal Cancer+13 more
Hoffmann-La Roche 534
Testing effectiveness (Phase 2)Looking for participantsNCT06010342
What this trial is testing

Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

Who this might be right for
Solid Tumor
Teligene US 60
Early research (Phase 1)Study completedNCT02675491
What this trial is testing

Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors

Who this might be right for
Advanced Solid Malignant Tumors
Daiichi Sankyo Co., Ltd. 15
Not applicableLooking for participantsNCT06837090
What this trial is testing

Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain (SPAINTRK)

Who this might be right for
Solid Neoplasms With NTRK Fusions
Grupo Espanol de Tumores Neuroendocrinos 19
Not applicableStudy completedNCT05793281
What this trial is testing

An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan

Who this might be right for
Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
Bayer 46,621
Early research (Phase 1)Study completedNCT04275960
What this trial is testing

Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body

Who this might be right for
Solid Tumors Harboring NTRK Fusion
Bayer 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Testing effectiveness (Phase 2)Looking for participantsNCT05745623
What this trial is testing

Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

Who this might be right for
Advanced Solid Tumors Harboring NTRK FusionPrimary Central Nervous System Tumors Harboring NTRK Fusion
Beijing InnoCare Pharma Tech Co., Ltd. 70
Load More Results